Literature DB >> 17059516

Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients.

E Durante-Mangoni1, R Zampino, A Marrone, M-F Tripodi, L Rinaldi, L Restivo, M Cioffi, G Ruggiero, L E Adinolfi.   

Abstract

BACKGROUND: Steatosis and insulin resistance (IR) have a pathogenic role in chronic hepatitis C (HCV). Adipocytokines balance modulates hepatic lipid content and IR. AIM: To evaluate serum adipocytokines and relationship with virological, histological and metabolic parameters in chronic HCV.
METHODS: Adiponectin and tumour necrosis factor-alpha (TNF-alpha) levels, HCV genotypes, HCV-RNA, IR (HOMA-IR), body mass index and liver steatosis and fibrosis were assessed in 161 non-diabetic chronic HCV patients.
RESULTS: Chronic HCV patients with steatosis showed lower serum adiponectin levels and higher levels of TNF-alpha, HOMA, alanine aminotransferase, gamma-glutamiltransferase and Histological Activity Index (HAI) and fibrosis scores. Low adiponectin levels were independently associated with grades of steatosis and HOMA-IR. Higher tumour necrosis factor-alpha levels were observed in patients with low adiponectin levels. The extension of steatosis was inversely correlated with adiponectin levels. A correlation between grade of steatosis with HOMA-IR and fibrosis was observed. HCV genotype 3-infected patients showed lower adiponectin levels than those with other genotypes. An independent predictor of low adiponectin levels in genotype 3 infection was the extension of steatosis. Liver fibrosis score was associated with steatosis, HAI and age.
CONCLUSIONS: Chronic HCV patients with steatosis showed a serum adiponectin/TNF-alpha imbalance that is associated with IR. Reduced adiponectin levels may be involved in the pathogenesis of steatosis, which in turn accelerates progression of fibrosis in chronic HCV.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17059516     DOI: 10.1111/j.1365-2036.2006.03114.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  35 in total

Review 1.  Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations.

Authors:  Rosa Zampino; Aldo Marrone; Luciano Restivo; Barbara Guerrera; Ausilia Sellitto; Luca Rinaldi; Ciro Romano; Luigi E Adinolfi
Journal:  World J Hepatol       Date:  2013-10-27

Review 2.  Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis.

Authors:  Michał Kukla; Włodzimierz Mazur; Rafał J Bułdak; Krystyna Zwirska-Korczala
Journal:  Mol Med       Date:  2011-07-05       Impact factor: 6.354

3.  Endotoxinemia contributes to steatosis, insulin resistance and atherosclerosis in chronic hepatitis C: the role of pro-inflammatory cytokines and oxidative stress.

Authors:  Rosa Zampino; Aldo Marrone; Luca Rinaldi; Barbara Guerrera; Riccardo Nevola; Adriana Boemio; Natalina Iuliano; Mauro Giordano; Nicola Passariello; Ferdinando C Sasso; Emanuele Albano; Luigi E Adinolfi
Journal:  Infection       Date:  2018-07-31       Impact factor: 3.553

Review 4.  Adiponectin serum level in chronic hepatitis C infection and therapeutic profile.

Authors:  Valentina Peta; Carlo Torti; Natasa Milic; Alfredo Focà; Ludovico Abenavoli
Journal:  World J Hepatol       Date:  2015-01-27

5.  Adiponectin attenuates lipopolysaccharide-induced acute lung injury through suppression of endothelial cell activation.

Authors:  Jason M Konter; Jennifer L Parker; Elizabeth Baez; Stephanie Z Li; Barbara Ranscht; Martin Denzel; Frederic F Little; Kazuto Nakamura; Noriyuki Ouchi; Alan Fine; Kenneth Walsh; Ross S Summer
Journal:  J Immunol       Date:  2011-12-07       Impact factor: 5.422

Review 6.  Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients.

Authors:  Roger Bedimo; Oladapo Abodunde
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

Review 7.  Steatosis as a co-factor in chronic liver diseases.

Authors:  Marcello Persico; Achille Iolascon
Journal:  World J Gastroenterol       Date:  2010-03-14       Impact factor: 5.742

Review 8.  Classic and Novel Adipocytokines at the Intersection of Obesity and Cancer: Diagnostic and Therapeutic Strategies.

Authors:  Nikolaos Spyrou; Konstantinos I Avgerinos; Christos S Mantzoros; Maria Dalamaga
Journal:  Curr Obes Rep       Date:  2018-12

Review 9.  Dysmetabolic changes associated with HCV: a distinct syndrome?

Authors:  Amedeo Lonardo; Paola Loria; Nicola Carulli
Journal:  Intern Emerg Med       Date:  2008-02-15       Impact factor: 3.397

10.  Helicobacter pylori infection does not promote hepatocellular cancer in a transgenic mouse model of hepatitis C virus pathogenesis.

Authors:  Alexis García; Yan Feng; Nicola M A Parry; Amanda McCabe; Melissa W Mobley; Kvin Lertpiriyapong; Mark T Whary; James G Fox
Journal:  Gut Microbes       Date:  2013-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.